Trial Profile

A Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3478006 in Healthy Subjects

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY 3478006 (Primary) ; LY 3478006 (Primary)
Indications Unspecified
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

20 Jul 2020 Status changed from suspended to discontinued.
16 Jun 2020 Planned End Date changed from 1 Feb 2021 to 4 Sep 2020.
16 Jun 2020 Planned primary completion date changed from 1 Feb 2021 to 4 Sep 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com